Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: Preparation, characterization and evaluation in guinea pigs

Vaccine

Volumn 25, Issue 37-38, 2007, Pages 6818-6829

  Amidi, Maryam ^a   Pellikaan, Hubert C ^b   Hirschberg, Hoang ^c   de Boer, Anne H ^d   Crommelin, Daan J A ^a   Hennink, Wim E ^a   Kersten, Gideon ^c   Jiskoot, Wim ^a,e  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Feyecon D and I BV   (Netherlands)

^c NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Diphtheria toxoid; N Trimethyl chitosan (TMC) microparticles; Pulmonary vaccine delivery; Supercritical carbon dioxide

Indexed keywords

CHITOSAN DERIVATIVE; DEXTRAN; DIPHTHERIA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M ANTIBODY; N TRIMETHYL CHITOSAN; NEUTRALIZING ANTIBODY; POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG SCREENING; FEMALE; GUINEA PIG; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LASER DIFFRACTION; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUPERCRITICAL FLUID; SUSTAINED RELEASE PREPARATION;

ANIMALS; CHITOSAN; DIPHTHERIA TOXOID; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; GUINEA PIGS; IMMUNOGLOBULINS; LUNG; MALE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; POWDERS; VACCINATION;

EID: 34548264691     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.064     Document Type: Article

References (62)

1. Patton J.S. Mechanisms of macromolecules absorption by the lungs. Adv Drug Del Rev 19 (1996) 3-36
2. Owens D.R., Zinman B., and Bollit G. Alternative routes of insulin delivery. Diabet Med 20 (2003) 886-898
3. Bienenstock J., and McDermott M.R. Bronchus- and nasal-associated lymphoid tissues. Immunol Rev 206 (2005) 22-31
4. Alpar H.O., Somavarapu S., Atuah K.N., and Bramwell V.W. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 57 (2005) 411-430
5. Patton J.S., Fishburn C.S., and Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 1 (2004) 338-344
6. Pilette C., Ouadrhiri Y., Godding V., Vaerman J.P., and Sibille Y. Lung mucosal immunity: immunoglobulin-A revisited. Eur Respir J 18 (2001) 571-588
7. Clements M.L., O'Donnel S., Levine M.M., Chanock R.M., and Murphy B.R. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun 40 (1983) 1044-1051
8. Liew F.Y., Russel S.M., Appleyard G., Brand C.M., and Beale J. Cross protection in mice infected with influenza A virus by the respiratory route is corrected with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol 14 (1984) 350-356
9. Underdown B.J., and Schiff J.M. Immunoglobulin A:strategic defense initiative at the mucosal surface. Annu Rev Immunol 4 (1986) 389-417
10. Ourth D.D. Neutralization of diphtheria toxin by human immunoglobulin classes and subunits. Immunochemistry 11 (1974) 223-225
11. Bivas-Benita M., Laloup M., Versteyhe S., Dewit J., De Braekeleer J., Jongert E., et al. Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization and preliminary in vivo studies. Int J Pharm 266 (2003) 17-27
12. van der Lubben I.M., Kersten G., Fretz M.M., Beuvery C., Verhoef J.C., and Junginger H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 28 (2003) 1400-1408
13. Vila A., Sanchez A., Janes K., Behrens I., Kissel T., Vila Jato J.L., et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 57 (2004) 123-131
14. van der Lubben I.M., Verhoef J.C., Fretz M.M., van Opdorp F.A.C., Mesu I., Kersten G., et al. Trimethyl chitosan chloride (TMC) as novel excipient for oral and nasal immunization against diphtheria. STP Pharm Sci 12 (2002) 235-242
15. Bivas-Benita M., van Meijgaarden K.E., Franken K.L., Junginger H.E., Borchard G., Ottenhoff T.H., et al. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of mycobacterium tuberculosis. Vaccine 22 (2004) 1609-1615
16. van der Lubben I.M., Konings F.A., Borchard G., Verhoef J.C., and Junginger H.E. In vivo uptake of chitosan microparticles by murine Peyer's patches: visualization studies using confocal laser scanning microscopy and immunohistochemistry. J Drug Target 9 (2001) 39-47
17. Amidi M., Romeijn S.G., Borchard G., Junginger H.E., Hennink W.E., and Jiskoot W. Preparation and characterization of protein-loaded N-Trimethyl chitosan nanoparticles as nasal delivery system. J Control Release 111 (2006) 107-116
18. McNeela E.A., Jabbal-Gill I., Illum L., Pizza M., Rappuoli R., Podda A., et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22 (2004) 909-914
19. Hamman J.H., Stander M., and Kotzé A.F. Effect of the degree of quaternization of N-Trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia. Int J Pharm 232 (2002) 235-242
20. Thanou M., Verhoef J.C., Verheijden J.H.M., and Junginger H.E. Intestinal absorption of octeriotide: N-Trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J Pharm Sci 89 (2000) 951-957
21. Amidi M., Romeijn S.G., Verhoef J.C., Junginger H.E., Bungener L., Huckriede A., et al. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 25 (2007) 144-153
22. Alpar H.O., Eyles J.E., Williamson E.D., and Somavarapu S. Intranasal vaccination against plague, tetanus and diphtheria. Adv Drug Deliv Rev 51 (2001) 173-201
23. Rydell N., and Sjoholm I. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine 22 (2004) 1265-1274
24. Yeo S.D., Lim G.B., Debenedetti P.G., and Bernstein H. Formation of microparticulate protein powders using a supercritical fluid antisolvent. Biotech Bioeng 41 (1993) 341-346
25. Elvassore N., Bertucco A., and Caliceti P. Production of insulin-loaded poly(ethylene glycol)/poly(l-lactide) (PEG/PLA) nano-particles by gas antisolvent techniques. J Pharm Sci 90 (2001) 1628-1636
26. Tservistas M., Levy M.S., Lo-Yim M.Y., O'Kennedy R.D., York P., Humphrey G.O., et al. The formation of plasmid DNA loaded pharmaceutical powders using supercritical fluid technology. Biotech Bioeng 72 (2001) 12-18
27. Jovanovic N., Bouchard A., Hofland G.W., Witkamp G.J., Crommelin D.J.A., and Jiskoot W. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm Res 21 (2004) 1955-1969
28. Jovanovic N., Bouchard A., Hofland G.W., Witkamp G.J., Crommelin D.J.A., and Jiskoot W. Distinct effects of sucrose and trehalose on protein stability during supercritical fluid drying and freeze-drying. Eur J Pharm Sci 27 (2006) 336-345
29. Jiang X., van der Horst A., van Steenbergen M.J., Akeroyd N., van Nostrum C.F., Schoenmakers P.J., et al. Molar-mass characterization of cationic polymers for gene delivery by aqueous size-exclusion chromatography. Pharm Res 23 (2006) 595-603
30. Sieval A.B., Thanou M., Kotzé A.F., Verhoef J.C., Brussee J., and Junginger H.E. Preparation and NMR-characterisation of highly substituted N-Trimethyl chitosan chloride. Carbohydr Polym 36 (1998) 157-165
31. Hallworth G.W., and Andrews U.G. Size analysis of suspension inhalation aerosols by inertial separation methods. J Pharm Pharmacol 28 (1976) 898-907
32. de Boer A.H., Gjaltema D., Hagedoorn P., and Frijlink H.W. Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. Int J Pharm 249 (2002) 219-231
33. Hinds W.C. Acceleration and curvilinear particle motion. In: Hinds W.C. (Ed). Aerosol technology properties, behavior and measurement of airborne particles (1982), John Wiley & Sons, New York 104-126
34. Verweij W.R., de Haan L., Holtrop M., Agsteribbe E., Brands R., van Scharrenburg G.J., et al. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine 16 (1998) 2069-2076
35. de Haan L., Verweij W.R., Holtrop M., Brands R., van Scharrenburg G.J., Palache A.M., et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia Coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 19 (2001) 2898-2907
36. Miyamura K., Nishio S., Ito A., Murata R., and Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration. J Biol Stand 2 (1974) 198-201
37. Rappuoli R. New generation vaccines. In: Levine M.M., Woodrow G.C., Kaper J.B., and Cobon G.S. (Eds). New and improved vaccines against diphtheria and tetanus (1997), Marcel Dekker, New York 417-436
38. Kanke M., Sniecinski I., and DeLuca P.P. Interaction of microspheres with blood constituents: I. Uptake of polystyrene spheres by monocytes and granulocytes and effect on immune responsiveness of lymphocytes. J Parenter Sci Technol 37 (1983) 210-217
39. Tabata Y., and Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9 (1988) 356-362
40. Baudner B.C., Morandi M., Giuliani M.M., Verhoef J.C., Junginger H.E., Costantino P., et al. Modulation of immune response to group C meningococal conjugate vaccine given intranasally to mice together with trimethyl chitosan delivery system. J Infect Dis 189 (2004) 828-832
41. Singh M., Briones M., and O'Hagan D.T. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 70 (2001) 267-276
42. Coulter A., Harris R., Davis R., Drane D., Cox J., Ryan D., et al. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 21 (2003) 946-949
43. Bramwell V.W., Somavarapu S., Outschoorn I., and Alpar H.O. Adjuvant action of melittin following intranasal immunisation with tetanus and diphtheria toxoids. J Drug Target 11 (2003) 525-530
44. Isaka M., Yasuda Y., Kozuka S., Taniguchi T., Matano K., Maeyama J., et al. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine 18 (2000) 743-751
45. Jenkins P.G., Coombes A.G., Yeh M.K., Thomas N.W., and Davis S.S. Aspects of the design and delivery of microparticles for vaccine applications. J Drug Target 3 (1995) 79-81
46. Coombes A.G., Lavelle E.C., Jenkins P.G., and Davis S.S. Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine 14 (1996) 1429-1438
47. Jabbal-Gill I., Lin W., Jenkins P., Watts P., Jimenez M., Illum L., et al. Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine 18 (1999) 238-250
48. Vu Q., McCarthy K.M., McCormack M., and Schneeberger E.E. Lung dendritic cells are primed by inhaled particulate antigens, and retain MHC class II/antigenic peptide complexes in hilar lymph nodes for a prolonged period of time. Immunology 105 (2002) 488-498
49. Newman K.D., Elamanchili P., Kwon G.S., and Samuel J. Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res 60 (2002) 480-486
50. Audran R., Peter K., Dannull J., Men Y., Scandella E., Groettrup M., et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 21 (2003) 1250-1255
51. Vidard L., Kovacsovics-Bankowski M., Kraeft S.K., Chen L.B., Benacerraf B., and Rock K.L. Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol 156 (1996) 2809-2818
52. Sun H.F., Pollock K.G.J., and Brewer J.M. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21 (2003) 849-855
53. Kotzé A.F., Lueßen H.L., de Leeuw B.J., de Boer A.G., Verhoef J.C., and Junginger H.E. Enhancement of paracellular drug transport with highly quaternised N-Trimethyl chitosan chloride in neutral environments: in vitro evaluation in intestinal epithelial cells (Caco-2). J Pharm Sci 88 (1999) 253-257
54. Snyman D., Hamman J.H., and Kotze A.F. Evaluation of the mucoadhesive properties of N-Trimethyl chitosan chloride. Drug Dev Ind Pharm 29 (2003) 61-69
55. Thiele L., Merkle H.P., and Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm Res 20 (2003) 221-228
56. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32 (1998) 155-172
57. Cox J., and Coulter A. Prospects for the development of new vaccine adjuvants. Biodrugs 12 (1999) 439-453
58. Snapper C.M., and Finkelman F.D. Immunoglobulin class switching. In: Paul W.E. (Ed). Fundamental immunology (1998), Lippincott-Raven, New York 831-861
59. Fowler K., McBride B.W., Turnbull P.C., and Baillie L.W. Immune correlates of protection against anthrax. J Appl Microbiol 87 2 (1999) 305
60. McBride B.W., Mogg A., Telfer J.L., Lever M.S., Miller J., Turnbull P.C., et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16 8 (1998) 810-817
61. Togashi H., and Tozawa H. Neutralization of sendai virus by the IgG subclass antibodies of the guinea pig. Microbiol Immunol 26 9 (1982) 821-829
62. Ito R., Ozaki Y.A., Yoshikawa T., Hasegawa H., Sato Y., Suzuki Y., et al. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 21 (2003) 2362-2371